Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months.
Baba Psalm Duniva InusaAdlette InatiPhilip MaesJessie GithangaBernhards OgutuMiguel R AbboudMaurizio MianoElena CelaVidelis NdubaMohammad NiaziMagnus ÅstrandKevin PerssonAnders BerggrenGlenn CarlsonPublished in: Pediatric blood & cancer (2021)
Inhibition of platelet activation may reduce vaso-occlusion rates in patients with sickle cell disease (SCD). In the HESTIA4 (NCT03492931) study, 21 children with SCD received a single oral dose of the antiplatelet agent ticagrelor (0.1 mg/kg <6 months; 0.2 mg/kg ≥6 to <24 months). All patients had measurable ticagrelor plasma concentrations. Ticagrelor and active metabolite (AR-C124910XX) exposure were comparable across all groups (<6 months, ≥6 to <12 months and ≥12 to <24 months). Ticagrelor was well tolerated. Palatability was generally acceptable. These data will be used to enable dose selection for further investigations of ticagrelor efficacy and safety in children with SCD.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- st elevation myocardial infarction
- st segment elevation myocardial infarction
- antiplatelet therapy
- end stage renal disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- young adults
- prognostic factors
- coronary artery disease
- big data
- electronic health record
- artificial intelligence
- deep learning